Selehold 360 mg spot-on solution for dogs 40.1 60.0 kg

Authorised

- Selamectin

Product identification

Medicine name:
Selehold 360 mg spot-on solution for dogs 40.1 60.0 kg
Selehold 360 mg kožni nanos, raztopina za pse od 40,1 do 60,0 kg

Active substance:
Selamectin

Target species:
Dog

Route of administration:
Spot-on use

Product details

Active substance and strength:
Selamectin
360.00 milligram(s) / 1.00 Pipette

Pharmaceutical form:
Spot-on solution

Withdrawal period by route of administration:

Spot-on use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP54AA05

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Slovenia

Package description:

Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spike packaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 6 ml pipette containing 3.0 ml of solution. Cardboard box containing 1 pipette.
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spike packaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 6 ml pipette containing 3.0 ml of solution. Cardboard box containing 3 pipettes.
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spike packaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 6 ml pipette containing 3.0 ml of solution. Cardboard box containing 6 pipettes.
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spike packaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 6 ml pipette containing 3.0 ml of solution. Cardboard box containing 15 pipettes.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:
4/10/2018

Manufacturing sites for batch release:
Krka d.d. Novo Mesto
Tad Pharma GmbH

Responsible authority:
Agency For Medicinal Products And Medical Devices Of The Republic Of Slovenia

Authorisation number:
DC/V/0639/006

Date of authorisation status change:
4/10/2018

Reference member state:
Ireland

Procedure number:
IE/V/0395/005

Concerned member states:
Belgium Bulgaria Croatia Czechia Estonia France Greece Hungary Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 11/02/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.
